Helsinn Healthcare S.A. et al. v. Mylan Institutional LLC

I'll research this case using web searches to verify the details.

Case Overview — Helsinn Healthcare S.A. et al. v. Mylan Institutional LLC, No. 1:14-cv-00709-GMS (D. Del.)

Parties and what they do. Both plaintiffs are operating, research-based pharmaceutical companies—not NPEs or PAEs. Helsinn Healthcare S.A. (Lugano, Switzerland) is a specialty pharmaceutical group that holds the New Drug Application for Aloxi® (palonosetron hydrochloride) injection, a 5-HT₃ receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV); in the U.S. Aloxi has been marketed by Helsinn's partner Eisai Co., Ltd. (DrugPatentWatch litigation summary; BioCentury, June 2, 2017). Roche Palo Alto LLC — the one-time Syntex/ Roche Palo Alto research entity, and a co-assignee of the patents — is the originator of the palonosetron molecule; Helsinn took an exclusive license to palonosetron and the related IP from Roche in 1998 (Fed. Cir., Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356, 1361 (2017); Delaware disclosure statement, D.I. 6 (naming Roche Holdings/Novartis affiliates)). The defendant, Mylan Institutional LLC, is a generic-drug subsidiary of Mylan (Mylan Inc. / Mylan N.V.), which filed an ANDA seeking approval to market a generic palonosetron injection. Mylan Inc. itself was named but was dismissed from this case by stipulation in August 2014 after moving to dismiss for lack of personal jurisdiction (D.I. 9, 23, 24).

Accused product, patents, and technical sketch. The accused conduct is Mylan Institutional's filing of an ANDA with a Paragraph IV certification challenging the palonosetron patents, triggering this § 271(e)(2) action. Helsinn received Mylan's paragraph IV notice in May 2014 (a May 16, 2014 letter as to the '219 patent; docket entry 3 of the case records the patentee's notice date as May 19, 2014, and that the listed patents expire January 30, 2024, with a 30-month stay deadline of November 19, 2016). Although the case metadata flags U.S. Patent No. 7,960,424 ("'424," Liquid pharmaceutical formulations of palonosetron), the complaint and the Rule 3/4 Report to the Commissioner list five patents: the '424, plus 7,947,724 and 7,947,725 ("pharmaceutically stable" palonosetron solutions, asserted claims covering the 0.05 mg/mL concentration and/or EDTA), 8,598,219 (a fixed 0.25 mg dose of palonosetron in 5 mL of solution with EDTA and mannitol, stable ≥24 months at room temperature), and 8,729,094 (liquid palonosetron formulations / methods of use). The '424 patent claimed, inter alia, a "pharmaceutically stable isotonic intravenous solution of palonosetron hydrochloride" comprising 0.03–0.2 mg/mL palonosetron, mannitol as tonicity agent, pH 4.0–6.0, and EDTA 0.005–1.0 mg/mL, with asserted claim 6 covering the 0.05 mg/mL / pH 4.5–5.5 formulation (DrugPatentWatch claim text). The '424 application (Ser. No. 11/388,270, filed March 24, 2006) claims priority back to U.S. Provisional 60/444,351 (Jan. 30, 2003), making the pre-AIA on-sale-bar critical date January 30, 2002.

Procedural posture and why the venue matters. Filed June 4, 2014 in the U.S. District Court for the District of Delaware, assigned to Judge Gregory M. Sleet (C.A. No. 14-709-GMS), a no-jury ANDA case. Delaware is the leading Hatch-Waxman forum, and Judge Sleet managed a large ANDA docket. Helsinn was simultaneously running a coordinated set of Delaware suits against other generic filers (e.g., Cipla, C.A. 13-688; Ben Venue, 13-1612; Accord, 13-2101; Fresenius Kabi, 15-865), and in November 2014 the court consolidated 14-709 into the Cipla lead case, C.A. 13-688-GMS, directing that all future filings be made in the lead case (D.I. 35, 36 (Nov. 10, 2014)). Claim-construction briefing and a February 18, 2015 Markman hearing proceeded in the consolidated action, with Mylan joining the disputed terms "pharmaceutically stable" and the '219 preamble (D.I. 32; 13-688 D.I. 119, 151, 159). The case ended without a merits ruling against Mylan: the parties stipulated to dismissal as to Mylan Institutional on September 30, 2015, which the court so-ordered on October 5, 2015—the same date the case is recorded as terminated (D.I. 37; Unicourt/CourtListener docket).

Why it is notable. First, market significance: Aloxi was a branded product for a large and growing CINV market, and the palonosetron patents were the subject of a wave of generic challenges. Second, legal significance: the '424 patent was one of the four Helsinn patents invalidated in the companion litigation Helsinn Healthcare S.A. v. Dr. Reddy's Labs./Teva (D.N.J., No. 11-3962), where the district court (Judge Cooper) held the patents valid and infringed (Nov. 13, 2015), but the Federal Circuit reversed, holding asserted claim 6 of the '424 patent (along with claims of the '724, '725, and '219 patents) invalid under the on-sale bar (Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017)); the Supreme Court affirmed in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. ___ (2019), holding that the AIA did not change the on-sale bar's application to secret sales. That ruling—arising from Helsinn's 2001 license/supply agreements with M

I'll research this case thoroughly using web search.

Let me dig deeper into the docket and related proceedings.

Let me get the specific dockets and the motion to dismiss disposition.

I'll research the counsel of record for the plaintiffs in this case.

Let me get the actual docket entries and confirm plaintiff-side counsel.

Let me pull the docket and the complaint itself to identify all plaintiff-side counsel.

I'll research the docket and counsel for this case.

Let me pull the full docket from CourtListener to confirm counsel entries and roles.

Let me verify the individual attorneys, their firms, and roles.